Aristotle Atlantic Partners LLC Sells 9,323 Shares of Abbott Laboratories $ABT

Aristotle Atlantic Partners LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 48.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 9,727 shares of the healthcare product maker’s stock after selling 9,323 shares during the quarter. Aristotle Atlantic Partners LLC’s holdings in Abbott Laboratories were worth $999,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ABT. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 2.4%

Shares of NYSE:ABT opened at $103.13 on Friday. The company has a market capitalization of $179.63 billion, a PE ratio of 33.38, a price-to-earnings-growth ratio of 2.00 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business has a fifty day moving average price of $91.61 and a two-hundred day moving average price of $101.33. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research reports. Leerink Partners lowered their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. JPMorgan Chase & Co. lifted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Oppenheimer dropped their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Bank of America cut their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.61.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.